Events

Innovative Health Initiative - Call Days - Call 12
JAN
Mon
19
JAN
Tue
20

Starts in 3 weeks from now

Location

Online

Programmes
Health

The Innovative Health Initiative (IHI) is organising IHI Call Days to inform stakeholders about the rules and procedures, the financial aspects and general information about IHI Call 12.

The schedule of the IHI Call Days is as follows:

  • Financial aspects of the proposal: Monday 19 January 2026 - 14:30 - 16:30
  • General information on call 12: Tuesday 20 February 2026 - 10:30 - 12:30
  • Rules and procedures for single-stage calls: Tuesday 20 February 2026 - 14:30 - 16:30


The IHI Call Days platform can also support you in your search for partners. The platform includes a networking module to find potential partners for your consortium and message them. The platform remains open for networking until the call deadline.

More information and registration on the IHI website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.